ARVO 2025 presentation: Comparison of blue light-induced damage (BLD) in albino and pigmented mice
This study aimed at comparing blue light-induced retinal injury in albino Balb/cJRj and pigmented C57BL/6JRj mice.
Learn more
ARVO 2025 presentation: Triamcinolone delays retinal atrophy in a mouse laser-induced geographic atrophy model
Limited treatment options for patients with geographic atrophy (GA) pose challenges to find proper positive controls in preclinical models. This study aimed to test the efficacy of subconjunctival administration of triamcinolone in a laser-induced mouse model of GA.
Learn more
ARVO 2025 presentation: Phosphate-buffered saline administered intravitreally at P12 blocks neovascularization in the mouse oxygen-induced retinopathy model
Intravitreally injected phosphate-buffered saline (PBS) is known to decrease neovascularization in the mouse oxygen-induced retinopathy (OIR) model, and it is commonly used as a vehicle control in preclinical studies evaluating therapeutic efficacy. This study aimed at evaluating the impact of intravitreally (IVT) administered PBS on neovascularization and revascularization at various timepoints after OIR induction. Aflibercept (Eylea®) was used as a reference control.
Learn more
ARVO 2025 presentation: Human cornea-on-a-chip – opportunities and challenges
Cornea is a tight barrier restricting topically administered drugs’ penetration into the eye. The aim of the study was to create a tight epithelial barrier both with primary and with transformed human corneal cells on a 96-well microfluidic platform.
Learn more
ARVO 2025 presentation: Thioredoxin system and HIF1a pathway activation by oxidative stress in human iPSC-RPE cells
In vitro: Retinal pigment epithelium (RPE) cells exhibit a high susceptibility to reactive oxygen species (ROS) due to their elevated metabolic activity. The accumulation of ROS is a critical factor contributing to the pathogenesis of both dry and wet forms of age-related macular degeneration (AMD). The thioredoxin (TRX) system represents one of the two primary thiol-dependent antioxidant defense mechanisms in mammalian cells. The objective of this study was to investigate the concentration-dependent activation and response of the TRX system to ROS induced by RPE specific exogenous oxidative agent, sodium iodate (NaIO3).
Learn more
ARVO 2025
The ARVO 2025 Annual Meeting is just around the corner! Our teams from Finland, Lithuania, and France are getting ready for the trip to Salt Lake City.
Learn more
The 8th Gene Therapy Summit in Boston – let’s connect!
Experimentica is attending to the 8th Gene Therapy Summit in Boston on March 25-27, 2025. Reach out to schedule a meeting with us!
Learn more
Experimentica is heading to BIO-Europe Spring 2025 in Milan
Come to meet us in BIO-Europe Spring 2025 in Milan! Our Executive Chairman Giedrius Kalesnykas and CBO Guillaume Demarne are attending the event on March 17-19, 2025.
Learn more
Experimentica UAB (Lithuania) receives full accreditation from AAALAC International
Experimentica UAB in Lithuania achieved a major accomplishment by receiving a full accreditation from AAALAC International for its outstanding work on animal welfare.
Learn more
Experimentica Oy Announces Appointment of New Managing Director
Experimentica Oy announces the appointment of a new Managing Director. The current CEO will transition to the role of Executive Chairman.
Learn more
